Trial Profile
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 31 Dec 2013 Protocol has been amended to add dasatinib 100mg, once per day.
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Dec 2011 Planned End Date changed from 1 Dec 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.